OKYO Pharma Limited (OKYO)Healthcare | Biotechnology | London, United Kingdom | NasdaqCM
1.55 USD
-0.14
(-8.284%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 1.58 +0.03 (1.935%) ⇧ (July 13, 2026, 5:21 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 4:08 a.m. EDT
The short-term outlook remains neutral due to conflicting signals: while the stock recently rallied off its lows, the statistical forecasting model offers a weak bearish lean with low confidence, suggesting the recent price action may be noise rather than a confirmed trend. For the long term, the company presents a mixed picture; although the multi-year price trajectory shows a net gain driven by a massive surge in the most recent year, the underlying fundamentals are severely impaired. The business is burning significant cash, holds negative book value, and trades at a negative forward P/E, indicating no near-term earnings visibility. While the recent rally suggests the market is pricing in potential catalysts like the upcoming Phase 3 trial results, the lack of a sustainable earnings engine and the precarious balance sheet prevent a bullish long-term rating. Finally, there is no dividend income to consider. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.035160 |
| AutoARIMA | 0.035555 |
| AutoETS | 0.035555 |
| AutoTheta | 0.041833 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 1.16 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.386 |
| Excess Kurtosis | -0.93 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 81,342,848 |
| Forward P/E | -7.75 |
| Beta | 0.05 |
| Website | https://okyopharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.34496123 |
| Address1 | 14/15 Conduit St |
| Address2 | Floor 4 |
| All Time High | 7.0 |
| All Time Low | 0.808 |
| Ask | 1.58 |
| Ask Size | 4 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 133,580 |
| Average Daily Volume3 Month | 73,809 |
| Average Volume | 73,809 |
| Average Volume10Days | 133,580 |
| Beta | 0.045 |
| Bid | 1.56 |
| Bid Size | 1 |
| Book Value | -0.089 |
| City | London |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United Kingdom |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.55 |
| Current Ratio | 0.576 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 1.67 |
| Day Low | 1.55 |
| Display Name | OKYO Pharma |
| Earnings Timestamp End | 1,723,561,200 |
| Earnings Timestamp Start | 1,723,561,200 |
| Ebitda | -6,252,605 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -8.887 |
| Enterprise Value | 55,569,892 |
| Eps Current Year | -0.1 |
| Eps Forward | -0.2 |
| Eps Trailing Twelve Months | -0.11 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.6091 |
| Fifty Day Average Change | -0.05910003 |
| Fifty Day Average Change Percent | -0.036728628 |
| Fifty Two Week Change Percent | -34.496124 |
| Fifty Two Week High | 3.349 |
| Fifty Two Week High Change | -1.799 |
| Fifty Two Week High Change Percent | -0.5371753 |
| Fifty Two Week Low | 1.42 |
| Fifty Two Week Low Change | 0.13 |
| Fifty Two Week Low Change Percent | 0.09154929 |
| Fifty Two Week Range | 1.42 - 3.349 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,652,794,200,000 |
| Float Shares | 20,545,855 |
| Forward Eps | -0.2 |
| Forward P E | -7.7499995 |
| Free Cashflow | -3,001,427 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 4 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -6,260,540 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.30408 |
| Held Percent Institutions | 0.20811 |
| Implied Shares Outstanding | 52,479,257 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,743,379,200 |
| Long Business Summary | OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom. |
| Long Name | OKYO Pharma Limited |
| Market | us_market |
| Market Cap | 81,342,848 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_45535051 |
| Most Recent Quarter | 1,759,190,400 |
| Net Income To Common | -4,613,341 |
| Next Fiscal Year End | 1,774,915,200 |
| Non Diluted Market Cap | 88,689,944 |
| Number Of Analyst Opinions | 3 |
| Open | 1.67 |
| Operating Cashflow | -3,097,992 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 44 20 7495 2379 |
| Post Market Change | 0.03000009 |
| Post Market Change Percent | 1.9354898 |
| Post Market Price | 1.58 |
| Post Market Time | 1,783,977,688 |
| Previous Close | 1.69 |
| Price Eps Current Year | -15.499999 |
| Price Hint | 4 |
| Price To Book | -17.41573 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.527 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | -0.14 |
| Regular Market Change Percent | -8.28403 |
| Regular Market Day High | 1.67 |
| Regular Market Day Low | 1.55 |
| Regular Market Day Range | 1.55 - 1.67 |
| Regular Market Open | 1.67 |
| Regular Market Previous Close | 1.69 |
| Regular Market Price | 1.55 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 201,039 |
| Return On Assets | -1.0462899 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 52,479,257 |
| Shares Percent Shares Out | 0.00059999997 |
| Shares Short | 32,380 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 124,433 |
| Short Name | OKYO Pharma Limited |
| Short Percent Of Float | 0.0008 |
| Short Ratio | 0.51 |
| Source Interval | 15 |
| Symbol | OKYO |
| Target High Price | 13.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 9.0 |
| Target Median Price | 7.0 |
| Total Cash | 4,220,378 |
| Total Cash Per Share | 0.11 |
| Total Debt | 185,795 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.11 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.902905 |
| Two Hundred Day Average Change | -0.35290504 |
| Two Hundred Day Average Change Percent | -0.18545595 |
| Type Disp | Equity |
| Volume | 201,039 |
| Website | https://okyopharma.com |
| Zip | W1S 2XJ |